These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17030844)

  • 1. Blueprint for a stronger Food and Drug Administration.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2006 Oct; 355(17):1821. PubMed ID: 17030844
    [No Abstract]   [Full Text] [Related]  

  • 2. Protecting the health of the public--Institute of Medicine recommendations on drug safety.
    Psaty BM; Burke SP
    N Engl J Med; 2006 Oct; 355(17):1753-5. PubMed ID: 17030843
    [No Abstract]   [Full Text] [Related]  

  • 3. IOM: overhaul drug safety monitoring.
    Kuehn BM
    JAMA; 2006 Nov; 296(17):2075-6. PubMed ID: 17077364
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA responds to institute of medicine drug safety recommendations--in part.
    Psaty BM; Charo RA
    JAMA; 2007 May; 297(17):1917-20. PubMed ID: 17473302
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety concerns at the FDA.
    Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696
    [No Abstract]   [Full Text] [Related]  

  • 6. The Institute of Medicine report on the FDA: where is the science?
    Philipson T; Jena AB; Sun E
    Health Econ; 2007 Mar; 16(3):219-21. PubMed ID: 17315264
    [No Abstract]   [Full Text] [Related]  

  • 7. Both Urgency and Balance Needed in Addressing Opioid Epidemic: A Report From the National Academies of Sciences, Engineering, and Medicine.
    Bonnie RJ; Kesselheim AS; Clark DJ
    JAMA; 2017 Aug; 318(5):423-424. PubMed ID: 28715551
    [No Abstract]   [Full Text] [Related]  

  • 8. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
    Psaty BM; Meslin EM; Breckenridge A
    JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
    [No Abstract]   [Full Text] [Related]  

  • 9. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of Flibanserin: Science and Advocacy at the FDA.
    Gellad WF; Flynn KE; Alexander GC
    JAMA; 2015 Sep; 314(9):869-70. PubMed ID: 26148201
    [No Abstract]   [Full Text] [Related]  

  • 11. Trouble at the FDA: can we fix the problems affecting you and your patients?
    Henley E
    J Fam Pract; 2006 Apr; 55(4):301-4. PubMed ID: 16608668
    [No Abstract]   [Full Text] [Related]  

  • 12. Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion.
    Bunney WE; Azarnoff DL; Brown BW; Cancro R; Gibbons RD; Gillin JC; Hullett S; Killam KF; Kupfer DJ; Krystal JH; Stolley PD; French GS; Pope AM
    Arch Gen Psychiatry; 1999 Apr; 56(4):349-52. PubMed ID: 10197830
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics.
    Tilson HH; Madre LK; Califf RM
    Clin Pharmacol Ther; 2007 Aug; 82(2):118-21. PubMed ID: 17632533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FDA and the IOM report.
    Galson SK
    N Engl J Med; 2007 Dec; 357(24):2520-1; author reply 2521-2. PubMed ID: 18077820
    [No Abstract]   [Full Text] [Related]  

  • 15. The report of the Institute of Medicine on drug safety.
    Somberg J
    Am J Ther; 2007; 14(1):1-2. PubMed ID: 17303967
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical devices and health--creating a new regulatory framework for moderate-risk devices.
    Challoner DR; Vodra WW
    N Engl J Med; 2011 Sep; 365(11):977-9. PubMed ID: 21830961
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug advisory committees. Getting outside advice for close calls.
    Farley D
    FDA Consum; 1995 Mar; 29(2):23-6. PubMed ID: 10172354
    [No Abstract]   [Full Text] [Related]  

  • 18. Remarks of the Acting FDA Commissioner: FDLI's 48th annual conference.
    Crawford LM
    Food Drug Law J; 2005; 60(2):99-102. PubMed ID: 16097087
    [No Abstract]   [Full Text] [Related]  

  • 19. Can the Institute of Medicine review the FDA?
    Carroll BJ
    Nat Med; 2005 Apr; 11(4):369. PubMed ID: 15812509
    [No Abstract]   [Full Text] [Related]  

  • 20. The FDA in 2006: reasons for optimism.
    Chabner BA; Roberts TG
    Oncologist; 2007 Mar; 12(3):247-9. PubMed ID: 17405888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.